Germany’s Merck will acquire cCAM Biotherapeutics, the Israeli developer of cancer immunotherapies, for an estimated $600 million. cCAM is developing CM-24, for the treatment of melanoma and certain lung, bladder, gastric, colorectal and ovarian cancers.

http://www.haaretz.com/business/1.668381